Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SunWay Biotech CoROCO:1271 -0.50%82 EV-to-EBIT is 25.13 as of Sep. 06, 2026, which is 1% above its 10-year median of 24.86. GuruFocus rates ROCO:1271 with a GF Score™ of 82/100 and a GF Value™ of NT$113.42 (Significantly Undervalued). The stock has 8 warning signs investors should review. Among 1,568 Consumer Packaged Goods companies, SunWay Biotech Co ranks worse than 79.15% on this metric.
The historical rank and industry rank for SunWay Biotech Co's EV-to-EBIT or its related term are showing as below:
ROCO:1271'
s EV-to-EBIT Range Over the Past 10 Years
Min: 7.56 Med: 24.86 Max: 68.67
Current: 25.13
During the past 7 years, the highest EV-to-EBIT of SunWay Biotech Co was 68.67. The lowest was 7.56. And the median was 24.86.
ROCO:1271's EV-to-EBIT is ranked worse than 79.15% of 1568
companies
in the Consumer Packaged Goods industry
Industry Median: 12.51
vs ROCO:1271: 25.13
SunWay Biotech Co (ROCO:1271) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
SunWay Biotech Co's Enterprise Value for the quarter that ended in Jun. 2026 was NT$4,681 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SunWay Biotech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$178 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SunWay Biotech Co EV-to-EBIT Related Terms
SunWay Biotech Co EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for SunWay Biotech Co's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Packaged Foods subindustry, SunWay Biotech Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SunWay Biotech Co EV-to-EBIT vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, SunWay Biotech Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where SunWay Biotech Co's EV-to-EBIT falls into.
SunWay Biotech Co's current Enterprise Value is NT$4,482 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. SunWay Biotech Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 was NT$178 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SunWay Biotech Co (ROCO:1271) has a EV-to-EBIT of 25.13 as of Sep. 06, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on SunWay Biotech Co and its competitors. This is near median its historical median of 24.86. Over the past decade, SunWay Biotech Co's EV-to-EBIT has ranged from 7.56 to 68.67. According to the industry distribution chart, SunWay Biotech Co ranks #1241 out of 1568 companies in the Consumer Packaged Goods industry, placing it in the top 79.1%.
Is SunWay Biotech Co's EV-to-EBIT too high?
SunWay Biotech Co's current EV-to-EBIT of 25.13 is near median its 10-year median of 24.86. Over the past 10 years, this metric has ranged from a low of 7.56 to a high of 68.67. The Consumer Packaged Goods industry median EV-to-EBIT is 12.51. SunWay Biotech Co's value of 25.13 is 100.9% above this industry median. Based on the distribution chart, SunWay Biotech Co ranks #1241 out of 1568 companies in the Consumer Packaged Goods industry, which is in the bottom quartile relative to peers. Overall, SunWay Biotech Co has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does SunWay Biotech Co's EV-to-EBIT compare to KHC and GIS?
According to the Consumer Packaged Goods industry distribution chart, SunWay Biotech Co ranks #1241 out of 1568 companies for EV-to-EBIT. This places SunWay Biotech Co in the lower half of its industry. The industry median EV-to-EBIT is 12.51. SunWay Biotech Co's value of 25.13 is 100.9% above this benchmark. Historically, SunWay Biotech Co's own EV-to-EBIT has ranged from 7.56 to 68.67 over the past decade. While the company's 10-year median is 24.86 vs. the industry median of 12.51, SunWay Biotech Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Consumer Packaged Goods company?
The median EV-to-EBIT among Consumer Packaged Goods companies is 12.51, based on 1,568 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SunWay Biotech Co's current EV-to-EBIT of 25.13 is 100.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on SunWay Biotech Co and its competitors. For the Consumer Packaged Goods industry, the median EV-to-EBIT is 12.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SunWay Biotech Co's current EV-to-EBIT is 25.13, which is near median its own 10-year median of 24.86. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SunWay Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, SunWay Biotech Co (ROCO:1271) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$113.42, compared to a current price of NT$59.20 — trading 47.8% below its estimated fair value. The current EV-to-EBIT is 25.13, which is near median its 10-year median of 24.86 and 100.9% above the Consumer Packaged Goods industry median of 12.51. SunWay Biotech Co's overall GF Score™ is 82/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For SunWay Biotech Co (ROCO:1271), the current EV-to-EBIT is 25.13 as of Sep. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SunWay Biotech Co (ROCO:1271) Overvalued in 2026?
Based on GuruFocus' analysis, SunWay Biotech Co stock appears to be undervalued.
The current stock price of NT$59.20 is trading 47.8% below its estimated GF Value™ of NT$113.42.
GuruFocus considers SunWay Biotech Co to be Significantly Undervalued.
Key valuation signals for ROCO:1271:
EV-to-EBIT: 25.13 (near median its 10-year median of 24.86)
GF Value™: NT$113.42 vs. price of NT$59.20 (47.8% below fair value)
Industry Position: 100.9% above the Consumer Packaged Goods median (#1241 of 1568)
No single metric tells the full story. See the ROCO:1271 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
SunWay Biotech Co Ltd is engaged in the research, design and manufacturing of Monascus purpureus NTU 568, Lactobacillus paracasei subsp, paracasei NTU 101, and the related products.
82GF Score
Get the complete analysis for ROCO:1271
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:1271 has been successfully added to your 
